Drug Trial Radar · NCT05879523
A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Oct 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Jun 5, 2023
Primary completion
Mar 21, 2024
Study completion Mar 21, 2024
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this phase Ⅰ study is to evaluate the safety, tolerability and pharmacokinetics of HRS-1893 in healthy volunteers and patients with obstructive hypertrophic cardiomyopathy
Conditions
- Obstructive Hypertrophic Cardiomyopathy
Interventions
HRS-1893Drug
subcutaneous, single dose, multiple doses
PlaceboDrug
subcutaneous, single dose, multiple doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- incidence of adverse event (AE), serious adverse event (SAE)Time frame: Start of Treatment to end of study (approximately 34 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.